SEARCH:   Advanced

Blood, 15 September 2004, Vol. 104, No. 6, pp. 1616-1623. Prepublished online as a Blood First Edition Paper on April 1, 2004; DOI 10.1182/blood-2003-12-4207. This Article Full Text Full Text (PDF) All Versions of this Article: 2003-12-4207v1 104/6/1616    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ho, A. Y. L. Articles by Mufti, G. J. Search for Related Content PubMed PubMed Citation Articles by Ho, A. Y. L. Articles by Mufti, G. J. Related Collections Transplantation Clinical Trials and Observations Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  CLINICAL OBSERVATIONS, INTERVENTIONS, AND THERAPEUTIC TRIALS Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning Aloysius Y. L. Ho, Antonio Pagliuca, Michelle Kenyon, Jane E. Parker, Aleksandar Mijovic, Stephen Devereux, and Ghulam J. Mufti From the Department of Haematological Medicine, King's College Hospital, Denmark Hill, London, United Kingdom. Reduced-intensity conditioned (RIC) hematopoietic stem cell transplantation (HSCT) has improved the accessibility of transplantation in patients previously ineligible. We report the results of allografting following conditioning with fludarabine, busulphan, and alemtuzumab in 62 patients with myelodysplastic syndromes (MDSs) (matched sibling donors [24] or volunteer unrelated donors [VUDs, 38]). The median age for sibling recipients was 56 years (range, 41-70 years) and for VUD recipients, 52 years (range, 22-65 years), with a median follow-up (survivors) of 524 days (range, 93-1392 days) and 420 days (range, 53-1495 days), respectively. The nonrelapse mortality (NRM) at days 100, 200, and 360 was 0%, 5%, and 5%, respectively, for siblings and 11%, 17%, and 21%, respectively, for VUD. The overall survival at one year was 73% for siblings and 71% for VUDs, with a disease-free survival (DFS) of 61% and 59%, respectively. The prognostic significance of the International Prognostic Scoring System (IPSS) was preserved. Of recipients, 86% achieved full-donor chimerism. The cumulative incidence at day 100 of grades III to IV graft-versus-host disease (GVHD) for VUD recipients was 9% and for sibling recipients, 0%. There were 26 patients (16 sibling and 10 VUD) who received donor lymphocyte infusion (DLI) at a median of 273 days (range, 126-1323 days). RIC allogeneic HSCT using this protocol appears to be safe and permits durable donor engraftment. Longer follow-up is required to confirm any potential survival advantage. (Blood. 2004;104:1616-1623) CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: R. Marks, K. Potthoff, J. Hahn, G. Ihorst, H. Bertz, A. Spyridonidis, E. Holler, and J. M. Finke Reduced-toxicity conditioning with fludarabine, BCNU, and melphalan in allogeneic hematopoietic cell transplantation: particular activity against advanced hematologic malignancies Blood, July 15, 2008; 112(2): 415 - 425. [Abstract] [Full Text] [PDF] D. Valcarcel, R. Martino, D. Caballero, J. Martin, C. Ferra, J. B. Nieto, A. Sampol, M. T. Bernal, J. L. Pinana, L. Vazquez, et al. Sustained Remissions of High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome After Reduced-Intensity Conditioning Allogeneic Hematopoietic Transplantation: Chronic Graft-Versus-Host Disease Is the Strongest Factor Improving Survival J. Clin. Oncol., February 1, 2008; 26(4): 577 - 584. [Abstract] [Full Text] [PDF] N. Omidvar, S. Kogan, S. Beurlet, C. le Pogam, A. Janin, R. West, M.-E. Noguera, M. Reboul, A. Soulie, C. Leboeuf, et al. BCL-2 and Mutant NRAS Interact Physically and Functionally in a Mouse Model of Progressive Myelodysplasia Cancer Res., December 15, 2007; 67(24): 11657 - 11667. [Abstract] [Full Text] [PDF] A. A. Jakubowski, T. N. Small, J. W. Young, N. A. Kernan, H. Castro-Malaspina, K. C. Hsu, M.-A. Perales, N. Collins, C. Cisek, M. Chiu, et al. T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin Blood, December 15, 2007; 110(13): 4552 - 4559. [Abstract] [Full Text] [PDF] M. L. Sorror, B. M. Sandmaier, B. E. Storer, M. B. Maris, F. Baron, D. G. Maloney, B. L. Scott, H. J. Deeg, F. R. Appelbaum, and R. Storb Comorbidity and Disease Status Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation J. Clin. Oncol., September 20, 2007; 25(27): 4246 - 4254. [Abstract] [Full Text] [PDF] D. Creamer, C. L. Martyn-Simmons, G. Osborne, M. Kenyon, J. R. Salisbury, S. Devereux, A. Pagliuca, A. Y. Ho, G. J. Mufti, and A. W. P. du Vivier Eczematoid Graft-vs-Host Disease: A Novel Form of Chronic Cutaneous Graft-vs-Host Disease and Its Response to Psoralen UV-A Therapy Arch Dermatol, September 1, 2007; 143(9): 1157 - 1162. [Abstract] [Full Text] [PDF] M Devetten and J. Armitage Hematopoietic cell transplantation: progress and obstacles Ann. Onc., September 1, 2007; 18(9): 1450 - 1456. [Abstract] [Full Text] [PDF] E. Estey, M. de Lima, R. Tibes, S. Pierce, H. Kantarjian, R. Champlin, and S. Giralt Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS) Blood, February 15, 2007; 109(4): 1395 - 1400. [Abstract] [Full Text] [PDF] C. G. Brunstein, D. J. Weisdorf, T. DeFor, J. N. Barker, J. Tolar, J.-A. H. van Burik, and J. E. Wagner Marked increased risk of Epstein-Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation Blood, October 15, 2006; 108(8): 2874 - 2880. [Abstract] [Full Text] [PDF] R. Martino, S. Iacobelli, R. Brand, T. Jansen, A. van Biezen, J. Finke, A. Bacigalupo, D. Beelen, J. Reiffers, A. Devergie, et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes Blood, August 1, 2006; 108(3): 836 - 846. [Abstract] [Full Text] [PDF] J. K. Davies, D. C. Taussig, H. Oakervee, A. J. Davies, S. G. Agrawal, J. G. Gribben, T. A. Lister, and J. D. Cavenagh Long-Term Follow-Up After Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia/Myelodysplastic Syndrome: Late CNS Relapses Despite Graft-Versus-Host Disease J. Clin. Oncol., May 10, 2006; 24(14): e23 - e25. [Full Text] [PDF] B. L. Scott and B. M. Sandmaier Outcomes with Myeloid Malignancies Hematology, January 1, 2006; 2006(1): 381 - 389. [Abstract] [Full Text] [PDF] S. Tauro, C. Craddock, K. Peggs, G. Begum, P. Mahendra, G. Cook, J. Marsh, D. Milligan, A. Goldstone, A. Hunter, et al. Allogeneic Stem-Cell Transplantation Using a Reduced-Intensity Conditioning Regimen Has the Capacity to Produce Durable Remissions and Long-Term Disease-Free Survival in Patients With High-Risk Acute Myeloid Leukemia and Myelodysplasia J. Clin. Oncol., December 20, 2005; 23(36): 9387 - 9393. [Abstract] [Full Text] [PDF] L. Chan, D. Nesbeth, T. MacKey, J. Galea-Lauri, J. Gaken, F. Martin, M. Collins, G. Mufti, F. Farzaneh, and D. Darling Conjugation of Lentivirus to Paramagnetic Particles via Nonviral Proteins Allows Efficient Concentration and Infection of Primary Acute Myeloid Leukemia Cells J. Virol., October 15, 2005; 79(20): 13190 - 13194. [Abstract] [Full Text] [PDF] E. Roman, E. Cooney, L. Harrison, O. Militano, K. Wolownik, R. Hawks, S. Foley, P. Satwani, E. Unal, M. Bhatia, et al. Preliminary Results of the Safety of Immunotherapy with Gemtuzumab Ozogamicin following Reduced Intensity Allogeneic Stem Cell Transplant in Children with CD33+ Acute Myeloid Leukemia Clin. Cancer Res., October 1, 2005; 11(19): 7164s - 7170s. [Abstract] [Full Text] [PDF] A. Spyridonidis, H. Bertz, G. Ihorst, C. Grullich, and J. Finke Hematopoietic cell transplantation from unrelated donors as an effective therapy for older patients (>= 60 years) with active myeloid malignancies Blood, May 15, 2005; 105(10): 4147 - 4148. [Full Text] [PDF] H. J. Deeg Optimization of Transplant Regimens for Patients with Myelodysplastic Syndrome (MDS) Hematology, January 1, 2005; 2005(1): 167 - 173. [Abstract] [Full Text] [PDF] S. Giralt Reduced-Intensity Conditioning Regimens for Hematologic Malignancies: What Have We Learned over the Last 10 Years? Hematology, January 1, 2005; 2005(1): 384 - 389. [Abstract] [Full Text] [PDF]

	Blood Online is supported in part by Genentech BioOncology and Biogen Idec
	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020